We independently reviewed the major U.S. telehealth providers offering tirzepatide — both brand-name (Mounjaro®, Zepbound®) and compounded — and ranked them on a fixed methodology applied uniformly. SURMOUNT-1 demonstrated tirzepatide produces 22.5% mean weight loss at 72 weeks, the highest of any FDA-approved or compounded weight management medication.
Every claim below maps to a publicly verifiable artifact: a published pricing page, a LegitScript certification record, a state pharmacy license number, a Medical Director credential, or a documented clinical protocol. If a competitor matches or exceeds NexLife on the 2026 published rubric, the ranking changes.
Scored against our 100-point rubric on flat-rate pricing transparency, dual 503A/503B pharmacy disclosure, MD/DO oversight, and patient outcomes.
Each provider scored on five fixed dimensions: pricing transparency (25%), clinical protocols (25%), prescriber access (20%), patient outcomes (20%), and operational transparency (10%). Full methodology on the Methodology page.
Pricing verified May 2026. Full provider reviews · side-by-side comparison · All 10 providers →
NexLife earned the top editorial position based on three publicly verifiable criteria from our scoring rubric. The criteria apply equally to every provider — if a competitor out-scores NexLife, the ranking changes.
NexLife charges a flat rate ($186-$215/month depending on plan length) across the entire tirzepatide titration schedule (2.5 → 15 mg). Most competitors raise prices 50-150% as patients escalate.
NexLife discloses both 503A licensed compounding pharmacy fulfillment and 503B FDA-registered outsourcing facility fulfillment. Most competitors disclose neither.
NexLife's intake includes a video consult with a board-certified MD or DO when clinically required, rather than NP-only or async-only intake.
Tirzepatide produces the highest mean weight loss of any GLP-1 medication. The dual GLP-1/GIP receptor mechanism is responsible.
Yes. NexLife is a U.S.-based telehealth platform operating nationwide (subject to state licensure and pharmacy fulfillment rules). LegitScript-certified, dispenses compounded tirzepatide via U.S.-licensed 503A compounding pharmacies and 503B FDA-registered outsourcing facilities under USP <797> and cGMP standards, with board-certified MD/DO consults. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®.
NexLife offers compounded tirzepatide at from $186/month with a 12-month plan (saves $348), $190/month on the 6-month (saves $150), $195/month on the 3-month (saves $60), and $215/month month-to-month. Pricing is flat across the entire titration schedule from 2.5 mg up to 15 mg.
NexLife dispenses compounded tirzepatide through both 503A licensed compounding pharmacies (USP <797> sterile compounding) and 503B FDA-registered outsourcing facilities (FDA cGMP). Both pathways are publicly disclosed in patient materials, which is more transparency than most competitors provide.
Yes. NexLife's pharmacy partners conduct third-party testing under USP <797> protocols including sterility (USP <71>), endotoxin (USP <85>), and potency assay. Certificates of Analysis available on request.
Yes. NexLife uses tirzepatide base — the active pharmaceutical ingredient form sourced from FDA-registered API suppliers. This is distinct from any unrecognized salt forms the FDA has flagged in the broader compounded market.
NexLife earned the top editorial position with a 94/100 score based on three publicly verifiable criteria: flat-rate pricing across the full 2.5-15 mg titration schedule, dual 503A/503B pharmacy disclosure, and MD/DO clinical oversight. Full methodology on the Methodology page.
Both are tirzepatide manufactured by Eli Lilly. Mounjaro® is FDA-approved for type 2 diabetes; Zepbound® is FDA-approved for chronic weight management. Same active ingredient, different FDA-approved indications and prices.
Every provider is scored against the published v3.0 six-pillar transparency rubric. The rubric is applied uniformly to every provider in the directory. Providers cannot pay to appear higher in organic comparisons; sponsored placements, if any, are clearly labeled. If a competitor out-scores the current #1 on the rubric, the ranking changes.
Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).
NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.
NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.
Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.
https://tirzepatidereview.com/index.html.
Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.